PROCEPT BioRobotics Corp has announced its financial results for the third quarter of 2026, reporting a robust 18% increase in revenue compared to the same period last year. This performance is significant for the company as it continues to establish itself in the surgical robotics sector, particularly in urology. The results reflect the company's ongoing commitment to innovation and growth in a competitive industry.

PROCEPT BioRobotics, incorporated in Delaware, operates under the SIC classification of Surgical & Medical Instruments & Apparatus. The company trades on the Nasdaq under the ticker PRCT. In its recent filings, including the 8-K dated November 4, 2026, the company provided insights into its financial health and operational performance.

The filing details that PROCEPT reported total revenue of $98.3 million for Q3 2026, which marks an 18% increase from the same quarter in 2025. The company also noted that U.S. procedures exceeded 13,400, reflecting a 22% growth year-over-year. Larry Wood, the Chief Executive Officer, expressed optimism about the company's trajectory, stating, “As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan.”

The filing highlights several key financial metrics: U.S. revenue was $85.8 million, representing a 16% increase compared to the prior year, while international revenue surged by 32% to $12.5 million. The gross margin for the quarter was 66%, up from 65% in the previous year. However, the company reported a net loss of $26.5 million for the quarter, compared to a loss of $21.4 million in Q3 2025.

This growth in revenue and procedures may impact various stakeholders, including investors, healthcare providers, and competitors within the surgical and medical instruments sector. The filing indicates that PROCEPT is also focused on expanding its installed base and enhancing utilization rates for its HYDROS systems, which are critical for its business model.

Looking ahead, PROCEPT BioRobotics has reaffirmed its full-year guidance, expecting revenue to range between $390 million and $410 million, which translates to a growth of 27% to 33% year-over-year. The company anticipates U.S. procedure volumes to reach between 54,000 and 56,000 for the year, indicating a strong outlook for the remainder of 2026. The filing does not specify any upcoming votes or additional filings.